Cuorips Inc. AI Stock Analysis
Want to see JP:4894 full AI Analyst Report?
Cuorips Inc. (4894) AI Stock Analysis
Cuorips Inc.
(TSE/TYO:4894)
The overall score is low, driven primarily by poor financial performance and an unattractive valuation. The company is deeply unprofitable with significant cash burn, which is a major risk. Moderately positive technical trends provide some support but are insufficient to offset fundamental weaknesses.
Cuorips Inc. (4894) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 58.77B
- Dividend Yield
- ―
- Average Volume (3M)
- 141.59K
- Price to Earnings (P/E)
- -47.9
- Beta (1Y)
- 1.22
- Revenue Growth
- -79.99%
- EPS Growth
- -58.51%
- Country
- Japan
- Employees
- 51
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Cuorips Inc. Business Overview & Revenue Model
Company Description
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based...
Cuorips Inc. Financial Statement Overview
Summary
Financial performance is weak. While revenue growth is strong, escalating operating and net losses, declining gross margins, and deeply negative cash flows indicate a high-risk, unprofitable stage. The debt-free balance sheet is a positive, but it is overshadowed by the rapid cash burn.
Income Statement
22NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 128.59M | 212.33M | 175.21M | 23.10M | 38.28M | 13.91M |
| Gross Profit | 5.13M | 45.90M | 91.56M | -60.47M | -57.64M | -82.09M |
| EBITDA | -1.12B | -996.81M | -513.57M | -518.38M | -371.78M | -280.46M |
| Net Income | -1.14B | -1.02B | -644.34M | -632.18M | -452.08M | -375.34M |
Balance Sheet | ||||||
| Total Assets | 4.81B | 5.12B | 5.74B | 6.18B | 3.59B | 4.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.32B | 3.90B | 4.79B | 5.58B | 2.94B | 3.34B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 354.46M | 353.83M | 211.91M | 200.96M | 133.79M | 149.36M |
| Stockholders Equity | 4.44B | 4.75B | 5.53B | 5.98B | 3.45B | 3.90B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.10B | -892.81M | -474.83M | -412.18M | -249.45M |
| Operating Cash Flow | 0 | -1.06B | -812.62M | -451.06M | -401.61M | -220.76M |
| Investing Cash Flow | 0 | -7.59M | -117.99M | -33.50M | -8.97M | -28.44M |
| Financing Cash Flow | 0 | 176.84M | 143.11M | 3.12B | 10.69M | 48.54M |
Cuorips Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Positive. The current price of 6620.00 is below the 20-day moving average (MA) of 6674.00, above the 50-day MA of 6187.80, and above the 200-day MA of 6121.48, indicating a neutral trend. The MACD of 128.55 indicates Positive momentum. The RSI at 51.59 is Neutral, neither overbought nor oversold. The STOCH value of 54.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4894.
Cuorips Inc. Peers Comparison
Overall Rating
JP:497845Neutral- JP:489444Neutral
JP:777442Neutral
JP:459339Underperform
JP:777639Underperform
JP:459938Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4978 | 45Neutral | JPY 11.65B | -25.06 | ― | ― | -8.23% | -48.10% |
| JP:4894 | 44Neutral | JPY 58.79B | -47.85 | ― | ― | -79.99% | -58.51% |
| JP:7774 | 42Neutral | JPY 26.88B | -73.78 | ― | ― | 17.05% | 10.47% |
| JP:4593 | 39Underperform | JPY 31.99B | -13.76 | ― | ― | -51.55% | 52.19% |
| JP:7776 | 39Underperform | JPY 6.70B | -5.83 | ― | ― | -56.16% | 3.12% |
| JP:4599 | 38Underperform | JPY 7.46B | -3.94 | ― | ― | ― | 4.85% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4894 | Cuorips Inc. | 6620.00 | 210.00 | 3.28% | |
| JP:4593 | Healios KK | 228.00 | -223.00 | -49.45% | |
| JP:4599 | StemRIM Inc. | 117.00 | -161.00 | -57.91% | |
| JP:4978 | ReproCELL Inc. | 109.00 | -48.00 | -30.57% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 653.00 | 175.00 | 36.61% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026